Top Markets
#1 Ontology Gas Ontology Gas +25.71%
#2 EXOD EXOD +22.08%
#3 Verus Coin Verus Coin +20.52%
#4 Derive Derive +18.82%
#5 ETHGas ETHGas +16.86%
#6 Status Status +15.56%
#7 Geodnet Geodnet +14.76%
#8 Pons Pons +11.68%
#9 Collect on Fanable Collect on Fanable +10.92%
#10 Curve DAO Curve DAO +10.67%
Coin of the day
Ontology Gas Ontology Gas
Settings
Language
ENGLISH
Currency
USD
Theme
Nuo Therapeutics, Inc. Nuo Therapeutics, Inc.

Nuo Therapeutics, Inc.

AURX
Rank in Stocks #25544
Nuo Therapeutics, Inc. operates as a regenerative medicine company,... Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market. Central to their offerings is a technology that isolates components from a patient's own blood (autologous) to generate a platelet-based therapy, specifically tailored for the treatment of chronic wounds. Established in Houston, Texas, in 1998, the company underwent a name change from Cytomedix, Inc. to Nuo Therapeutics, Inc. in November 2014.
Share Price
$1.00
Last synced: 2026-08-19
Market Cap
$48.41M
Change (1 day)
0.00%
Change (1 year)
-41.86%
Country
US
Trade Nuo Therapeutics, Inc. (AURX)

Category

Healthcare
P/E ratio for Nuo Therapeutics, Inc. (AURX)
P/E ratio as of 2026 TTM: 0
According to Nuo Therapeutics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Nuo Therapeutics, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.